Guideline for medication management of symptoms in older palliative care patients (2025)_Chinese Journal of Evidence-Based Medicine

Authors：

LI Daiping ¹ , YANG Yanwu ² , ZHANG Yan ¹ ,  JIANG Yan ³ ,  YUE Jirong ¹ ,  DONG Birong ¹ ,  GE Meiling ¹ , National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University

1. Department of Geriatrics and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. Department of Emergency, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
3. Department of Nursing/Evidence-Based Nursing Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

JIANG Yan, Email: hxhljy2018@163.com; YUE Jirong, Email: yuejirong11@hotmail.com; DONG Birong, Email: birongdong123@outlook.com; GE Meiling, Email: gemeiling025@163.com

Keywords：

Older adults; Palliative care; Symptom management; Medication guideline

DOI：

10.7507/1672-2531.202602065

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Older patients at the end of life often present with multiple geriatric syndromes and comorbidities, resulting in complex symptom profiles and a high risk of medication-related harm. These challenges not only compromise quality of life at the end of life but also complicate clinical decision-making. Currently, there is a lack of systematic, age-specific guidelines for medication management of symptoms in older palliative care patients in China. This guideline is developed in accordance with the standards of the grading of recommendations, assessment, development, and evaluations (GRADE) system and the reporting items for practice guidelines in healthcare (RIGHT). It addresses 15 symptoms, including pain, dyspnea, and cough in elderly palliative care patients, resulting in 67 recommendations. Based on the best available evidence, an expert panel conducted structured discussions and formulated recommendations. This guideline aims to identify and recommend appropriate pharmacological treatments for common and refractory symptoms in older palliative care patients, and to provide guidance for healthcare professionals on safe, rational, and standardized medication use.

Citation： LI Daiping, YANG Yanwu, ZHANG Yan, JIANG Yan, YUE Jirong, DONG Birong, GE Meiling, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University. Guideline for medication management of symptoms in older palliative care patients (2025). Chinese Journal of Evidence-Based Medicine, 2026, 26(8): 869-889. doi: 10.7507/1672-2531.202602065 Copy

1.	Cruz-Oliver DM. Palliative care: an update[J]. Miss Med, 2017, 114(2): 110-115.
2.	Hu X, Yu SJ, Gao YC, et al. Health inequality in the disease burden of non-communicable diseases among the elderly from 1990 to 2021, and projections to 2050: a systematic analysis of global burden of disease study[J]. BMC Geriatr, 2025, 25(1): 693.
3.	Ijaopo EO, Zaw KM, Ijaopo RO, et al. A review of clinical signs and symptoms of imminent end-of-life in individuals with advanced illness[J]. Gerontol Geriatr Med, 2023, 9: 23337214231183243.
4.	Gon?alves F, Gaudêncio M, Rocha A, et al. A review on the management of symptoms in patients with incurable cancer[J]. Curr Oncol, 2025, 32(8): 433.
5.	Swetz KM, Kamal AH. Palliative care[J]. Ann Intern Med, 2018, 168(5): 33-48.
6.	Luo S, Chen W, Li J, et al. Association between multimorbidity and end-of-life outcomes among middle-aged and older adults: evidence from 28 countries[J]. J Am Med Direct Associat, 2025, 26(3): 105461.
7.	Llop-Medina L, Fu Y, Garcés-Ferrer J, et al. Palliative care in older people with multimorbidities: a scoping review on the palliative care needs of patients, carers, and health professionals[J]. Int J Environ Res Public Health, 2022, 19(6): 3195.
8.	海峽兩岸醫藥衛生交流協會全科醫學分會. 姑息治療與安寧療護基本用藥指南[J]. 中國全科醫學, 2021, 24(14): 1717-1734.
9.	Hagemann V, Bausewein C, Remi C. Off-label use in adult palliative care - more common than expected. A retrospective chart review[J]. Eur J Hosp Pharm, 2022, 29(6): 329-335.
10.	Gr?dalski T. Polypharmacy and medication errors on admission to palliative care[J]. Pol Arch Intern Med, 2019, 129(10): 659-666.
11.	Mozeluk NB, Gallo Acosta CM, Cunha Ferre MF, et al. Potentially inappropriate medication in older adults with palliative care at home[J]. Medicina (B Aires), 2024, 84(3): 487-495.
12.	李代萍, 王洋, 楊燕武, 等. 老年安寧療護患者癥狀管理用藥指南(2025)計劃書[J]. 中國循證醫學雜志, 2025, 25(12): 1384-1388.
13.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650): 924-926.
14.	Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64(4): 401-406.
15.	Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)[J]. J Clin Epidemiol, 2011, 64(4): 407-415.
16.	Guyatt GH, Alonso-Coello P, Schünemann HJ, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group[J]. J Clin Epidemiol, 2016, 80: 3-7.
17.	Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline[J]. J Clin Oncol, 2023, 41(4): 914-930.
18.	Principles of pain control in palliative care for adults. Guidance prepared by a working group of the ethical issues in medicine committee of the royal college of physicians[J]. J R Coll Physicians Lond, 2000, 34(4): 350-352.
19.	Hodgkinson S, Ruegger J, Field-Smith A, et al. Care of dying adults in the last days of life[J]. Clin Med (Lond), 2016, 16(3): 254-258.
20.	Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy[J]. Support Care Cancer, 2005, 13(11): 888-894.
21.	Nijland L, Schmidt P, Frosch M, et al. Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review[J]. Support Care Cancer, 2019, 27(1): 33-42.
22.	Wegman A, van der Windt D, van Tulder M, et al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee. A systematic review of evidence and guidelines[J]. J Rheumatol, 2004, 31(2): 344-354.
23.	Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis. A meta-analysis of randomised controlled trials[J]. Ann Rheum Dis, 2004, 63(8): 901-907.
24.	Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis[J]. Pain, 2009, 143(3): 238-245.
25.	Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis[J]. BMC Musculoskelet Disord, 2004, 5: 28.
26.	Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients[J]. Drug Saf, 2008, 31(6): 545-556.
27.	Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials[J]. Lancet, 2013, 382(9894): 769-779.
28.	Bosnjak S, Jelic S, Susnjar S, et al. Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study[J]. J Chemother, 2002, 14(2): 214-219.
29.	La Spina I, Porazzi D, Maggiolo F, et al. Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations[J]. Eur J Neurol, 2001, 8(1): 71-75.
30.	Takahashi H, Shimoyama N. A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain[J]. Int J Clin Oncol, 2010, 15(1): 46-51.
31.	Wen C, Wang M, Liu M, et al. Pregabalin combined with opioids for managing neuropathic pain in patients with cancer: a systematic review and meta-analysis of randomized controlled trials[J]. Pain Physician, 2025, 28(1): 1-10.
32.	Hui D, Bohlke K, Bao T, et al. Management of dyspnea in advanced cancer: ASCO guideline[J]. J Clin Oncol, 2021, 39(12): 1389-1411.
33.	Hui D, Maddocks M, Johnson MJ, et al. Management of breathlessness in patients with cancer: ESMO clinical practice guidelines[J]. ESMO Open, 2020, 5(6): e001038.
34.	Kloke M, Cherny N. Treatment of dyspnoea in advanced cancer patients: ESMO clinical practice guidelines[J]. Ann Oncol, 2015, 26(Suppl 5): v169-v173.
35.	Yamaguchi Y, Saif-Ur-Rahman KM, Nomura M, et al. Opioid prescription method for breathlessness due to non-cancer chronic respiratory diseases: a systematic review[J]. Int J Environ Res Public Health, 2022, 19(8): 4907.
36.	Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial[J]. JAMA Intern Med, 2020, 180(10): 1306-1314.
37.	Ekstrom M, Ferreira D, Chang S, et al. Effect of regular, low-dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: the BEAMS randomized clinical trial. Multicenter study randomized controlled trial research support, non-U. S. Gov't[J]. JAMA, 2022, 328(20): 2022-2032.
38.	Currow D, Louw S, McCloud P, et al. Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial[J]. Thorax, 2020, 75(1): 50-56.
39.	Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea[J]. BMJ, 2003, 327(7414): 523-528.
40.	Gomutbutra P, O'Riordan DL, Pantilat SZ. Management of moderate-to-severe dyspnea in hospitalized patients receiving palliative care[J]. J Pain Symptom Manage, 2013, 45(5): 885-891.
41.	Clemens KE, Klaschik E. Dyspnoea associated with anxiety-symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients[J]. Support Care Cancer, 2011, 19(12): 2027-2033.
42.	Kako J, Kobayashi M, Oosono Y, et al. Immediate effect of fan therapy in terminal cancer with dyspnea at rest: a meta-analysis[J]. Am J Hosp Palliat Care, 2020, 37(4): 294-299.
43.	Gallagher R, Roberts D. A systematic review of oxygen and airflow effect on relief of dyspnea at rest in patients with advanced disease of any cause[J]. J Pain Palliat Care Pharmacotherapy, 2004, 18(4): 3-15.
44.	Uronis HE, Currow DC, McCrory DC, et al. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis[J]. Br J Cancer, 2008, 98(2): 294-299.
45.	Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial[J]. Lancet, 2010, 376(9743): 784‐793.
46.	Hui D, Hernandez F, Urbauer D, et al. High-flow oxygen and high-flow air for dyspnea in hospitalized patients with cancer: a pilot crossover randomized clinical trial[J]. Oncologist, 2021, 26(5): 883-892.
47.	Hui D, Morgado M, Chisholm G, et al. High-flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: a phase Ⅱ randomized trial[J]. J Pain Sympt Manag, 2013, 46(4): 463-473.
48.	Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough[J]. J Int Med Res, 1983, 11(2): 92-100.
49.	Smith J, Owen E, Earis J, et al. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2006, 117(4): 831-835.
50.	陳夢婷, 肖小意, 余慧青, 等. 復方福爾可定糖漿與復方可待因口服溶液用于肺癌相關性咳嗽療效觀察[J]. 中華醫學雜志, 2023, 103(13): 975-980.
51.	喬敬敬. 不同劑量鹽酸氨溴索治療老年慢性支氣管炎的臨床效果對比[J]. 航空航天醫學雜志, 2018, 29(5): 593-595.
52.	于春紅. 鹽酸氨溴索與頭孢曲松鈉在老年慢性支氣管炎中的應用效果分析[J]. 中國實用醫藥, 2025, 20(13): 86-89.
53.	余權標, 謝鋒, 劉鐵柱, 等. 噻托溴銨聯合鹽酸氨溴索治療老年COPD急性期的療效觀察[J]. 北方藥學, 2016, 13(10): 14-15.
54.	凌方英. 抗生素聯合氨溴索治療老年慢性支氣管炎急性發作的臨床效果分析[J]. 心血管外科雜志(電子版), 2018, 7(3): 468-469.
55.	盧真其, 蔡勤聰, 王彩華, 等. 鹽酸氨溴索治療老年慢性支氣管炎急性發作的臨床分析[J]. 中國現代藥物應用, 2019, 13(9): 106-107.
56.	李抒菡. 鹽酸氨溴索治療老年慢性支氣管炎急性期的臨床效果觀察[J]. 中國醫藥指南, 2015, (16): 176-176.
57.	柴鶴萍. 老年慢性支氣管炎64例臨床分析[J]. 中國初級衛生保健, 2015, 29(3): 126.
58.	賀燕. 鹽酸氨溴索聯合頭孢曲松鈉治療老年慢性支氣管炎的效果[J]. 臨床合理用藥雜志, 2021, 14(7): 50-51.
59.	姬改娜, 薛世民, 周娟. 羧甲司坦片聯合CPAP治療老年OSAHS患者的效果[J]. 貴州醫藥, 2022, 46(6): 877-878.
60.	張君. 羧甲司坦口服液治療>65歲肺炎患者臨床觀察[J]. 中國實用醫藥, 2012, 7(23): 175-176.
61.	Tsai YS, Hsu LW, Wu MS, et al. Effects of tranexamic acid on hemoptysis: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Drug Investig, 2020, 40(9): 789-797.
62.	Mahalingam S, Rajendran G, Ramkumar A, et al. Effectiveness of inhalational tranexamic acid in patients with nonmassive hemoptysis-a systematic review and meta-analysis[J]. Lung, 2025, 203(1): 19.
63.	Ye M, Chen M, Wang C, et al. Nebulized tranexamic acid in the management of hemoptysis: an integrative review[J]. Lung, 2025, 203(1): 28.
64.	Wang Y, Wang X, Fu H, et al. Yunnan Baiyao adjuvant treatment for patients with hemoptysis: a systematic review and meta-analysis[J]. Evid Based Complement Alternat Med, 2022, 2022: 4931284.
65.	北京醫師協會呼吸內科專科醫師分會咯血診治專家共識編寫組. 咯血診治專家共識[J]. 中國呼吸與危重監護雜志, 2020, 19(1): 1-11.
66.	Howard WJ, Rosario EJ, Calhoon SL. Hemoptysis. Causes and a practical management approach[J]. Postgrad Med, 1985, 77(8): 53-57.
67.	Ruiz-García V, López-Briz E, Carbonell-Sanchis R, et al. Megestrol acetate for cachexia-anorexia syndrome. A systematic review[J]. J Cachexia Sarcopenia Muscle, 2018, 9(3): 444-452.
68.	Miller S, McNutt L, McCann MA, et al. Use of corticosteroids for anorexia in palliative medicine: a systematic review[J]. J Palliat Med, 2014, 17(4): 482-485.
69.	Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial[J]. Support Care Cancer, 2010, 18(8): 951-956.
70.	Mercadante S, Ripamonti C, Casuccio A, et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction[J]. Support Care Cancer, 2000, 8(3): 188-191.
71.	Peng X, Wang P, Li S, et al. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer[J]. World J Surg Oncol, 2015, 13: 50.
72.	Hisanaga T, Shinjo T, Morita T, et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction[J]. Jpn J Clin Oncol, 2010, 40(8): 739-745.
73.	Piechotta V, Adams A, Haque M, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, (11): CD012775.
74.	Franzén L, Nyman J, Hagberg H, et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy[J]. Ann Oncol, 1996, 7(6): 587-592.
75.	Lanciano R, Sherman DM, Michalski J, et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy[J]. Cancer Invest, 2001, 19(8): 763-772.
76.	Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial[J]. JAMA Oncol, 2020, 6(6): 895-899.
77.	Khuroo MS, Khuroo MS, Farahat KL, et al. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis[J]. J Gastroenterol Hepatol, 2005, 20(1): 11-25.
78.	Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding[J]. Health Technol Assess, 2007, 11(51): iii-iv, 1-164.
79.	Wang CH, Ma MH, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials[J]. Arch Intern Med, 2010, 170(9): 751-758.
80.	Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices[J]. Hepatology, 1989, 10(6): 958-961.
81.	Harris DG, Noble SI. Management of terminal hemorrhage in patients with advanced cancer: a systematic literature review[J]. J Pain Symptom Manage, 2009, 38(6): 913-927.
82.	Sharif S, Kang J, Sadeghirad B, et al. Pharmacological agents for procedural sedation and analgesia in the emergency department and intensive care unit: a systematic review and network meta-analysis of randomised trials[J]. Br J Anaesth, 2024, 132(3): 491-506.
83.	Assmann SL, Keszthelyi D, Kleijnen J, et al. Guideline for the diagnosis and treatment of Faecal Incontinence-A UEG/ESCP/ESNM/ESPCG collaboration[J]. United European Gastroenterol J, 2022, 10(3): 251-286.
84.	Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults[J]. Cochrane Database Syst Rev, 2013, (6): CD002116.
85.	Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea[J]. Gastroenterology, 1980, 79(6): 1272-1275.
86.	Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial[J]. J Clin Oncol, 1993, 11(1): 148-151.
87.	Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy[J]. Anticancer Drugs, 1993, 4(4): 443-445.
88.	Geller RB, Gilmore CE, Dix SP, et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients[J]. Am J Hematol, 1995, 50(3): 167-172.
89.	Dzier?anowski T, Zaj?c A, Cia?kowska-Rysz A, et al. Constipation in palliative care patients - clinical practice guidelines[J]. Palliat Med, 2025, 17: 1-13.
90.	Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review[J]. Am J Gastroenterol, 2021, 116(6): 1156-1181.
91.	Jesuyajolu DA, Abubakar AK, Kowe T, et al. The management of opioid-induced constipation in cancer and advanced illness: a meta-analysis[J]. J Pain Symptom Manage, 2024, 67(4): e285-e297.
92.	Hurdon V, Viola R, Schroder C. How useful is docusate in patients at risk for constipation. A systematic review of the evidence in the chronically ill[J]. J Pain Symptom Manage, 2000, 19(2): 130-136.
93.	Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase Ⅲ studies[J]. Int J Clin Pract, 2013, 67(7): 619-632.
94.	Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase Ⅱ study (SYMPHONY)[J]. World J Urol, 2017, 35(5): 827-838.
95.	Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE)[J]. Eur Urol, 2016, 70(1): 136-145.
96.	Herdman M, Nazir J, Hakimi Z, et al. Assessing preference-based outcome measures for overactive bladder: an evaluation of patient-reported outcome data from the BESIDE clinical trial[J]. Patient, 2017, 10(6): 677-686.
97.	Jiang F, Zhu L, Xu T, et al. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women-a multicenter, randomized, open-label, controlled comparison study[J]. Menopause, 2016, 23(4): 451-457.
98.	Ashrafi F, Mousavi S, Karimi M. Potential role of bupropion sustained release for cancer-related fatigue: a double-blind, placebo-controlled study[J]. Asian Pac J Cancer Prev, 2018, 19(6): 1547-1551.
99.	Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial-a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine[J]. Health Technol Assess, 2013, 17(7): 1-166.
100.	Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer[J]. Acta Psychiatr Scand Suppl, 1985, 320: 85-92.
101.	Eiser N, Harte R, Spiros K, et al. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD[J]. Copd, 2005, 2(2): 233-241.
102.	Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group[J]. J Clin Oncol, 2003, 21(10): 1937-1943.
103.	Friedli K, Guirguis A, Almond M, et al. Sertraline versus placebo in patients with major depressive disorder undergoing hemodialysis: a randomized, controlled feasibility trial[J]. Clin J Am Soc Nephrol, 2017, 12(2): 280-286.
104.	Higginson IJ, Brown ST, Oluyase AO, et al. Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial[J]. Lancet Respir Med, 2024, 12(10): 763-774.
105.	Hunter CN, Abdel-Aal HH, Elsherief WA, et al. Mirtazapine in cancer-associated anorexia and cachexia: a double-blind placebo-controlled randomized trial[J]. J Pain Symptom Manage, 2021, 62(6): 1207-1215.
106.	Kimmick GG, Lovato J, McQuellon R, et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen[J]. Breast J, 2006, 12(2): 114-122.
107.	Lacasse Y, Beaudoin L, Rousseau L, et al. Randomized trial of paroxetine in end-stage COPD[J]. Monaldi Arch Chest Dis, 2004, 61(3): 140-147.
108.	Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS[J]. Arch Gen Psychiatry, 2003, 60(7): 737-746.
109.	Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study[J]. Am J Psychiatry, 2000, 157(10): 1686-1689.
110.	Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease[J]. Am J Geriatr Psychiatry, 2000, 8(1): 66-74.
111.	Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program[J]. J Clin Oncol, 2003, 21(24): 4635-4641.
112.	O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial[J]. J Am Coll Cardiol, 2010, 56(9): 692-699.
113.	Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease[J]. Int Psychogeriatr, 2001, 13(2): 233-240.
114.	Rascol O, Cochen de Cock V, Pavy-Le Traon A, et al. Fluoxetine for the symptomatic treatment of multiple system atrophy: the MSA-FLUO trial[J]. Mov Disord, 2021, 36(7): 1704-1711.
115.	Razavi D, Allilaire JF, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients[J]. Acta Psychiatr Scand, 1996, 94(3): 205-210.
116.	Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy[J]. Breast Cancer Res Treat, 2005, 89(3): 243-249.
117.	Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease[J]. Am J Geriatr Psychiatry, 2010, 18(2): 136-145.
118.	Salehifar E, Azimi S, Janbabai G, et al. Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial[J]. BMC Cancer, 2020, 20(1): 158.
119.	van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin[J]. Br J Psychiatry, 1996, 169(4): 440-443.
120.	Ainsworth NJ, Marawi T, Maslej MM, et al. Cognitive outcomes after antidepressant pharmacotherapy for late-life depression: a systematic review and meta-analysis[J]. Am J Psychiatry, 2024, 181(3): 234-245.
121.	Candy B, Jackson KC, Jones L, et al. Drug therapy for symptoms associated with anxiety in adult palliative care patients[J]. Cochrane Database Syst Rev, 2012, (10): CD004596.
122.	Kotlinska-Lemieszek A, Klepstad P, Haugen DF. Clinically significant drug-drug interactions involving medications used for symptom control in patients with advanced malignant disease: a systematic review[J]. J Pain Symptom Manage, 2019, 57(5): 989-998.
123.	Centeno C, Sanz A, Cuervo MA, et al. Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients[J]. BMJ Support Palliat Care, 2012, 2(4): 328-333.
124.	Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial[J]. J Pain Symptom Manage, 2012, 43(1): 68-77.
125.	Stone PC, Minton O, Richardson A, et al. Methylphenidate versus placebo for treating fatigue in patients with advanced cancer: randomized, double-blind, multicenter, placebo-controlled trial[J]. J Clin Oncol, 2024, 42(20): 2382-2392.
126.	王雪芹, 于欣, 高旭光, 等. 唑吡坦治療老年原發性失眠的開放性前瞻性多中心自身對照研究[J]. 中華精神科雜志, 2010, 43(2): 106-110.
127.	Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety[J]. BMC Med, 2010, 8: 51.
128.	Marupuru S, Arku D, Campbell AM, et al. Use of melatonin and/on ramelteon for the treatment of insomnia in older adults: a systematic review and meta-analysis[J]. J Clin Med, 2022, 11(17): 1-17.
129.	Agar MR, Lawlor PG, Quinn S, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial[J]. JAMA Intern Med, 2017, 177(1): 34-42.
130.	Bush SH, Bruera E, Lawlor PG, et al. Clinical practice guidelines for delirium management: potential application in palliative care[J]. J Pain Symptom Manage, 2014, 48(2): 249-258.
131.	Hui D, Frisbee-Hume S, Wilson A, et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial[J]. JAMA, 2017, 318(11): 1047-1056.
132.	Ferraz Gon?alves JA, Almeida A, Costa I, et al. Comparison of haloperidol alone and in combination with midazolam for the treatment of acute agitation in an inpatient palliative care service[J]. J Pain Palliat Care Pharmacother, 2016, 30(4): 284-288.
133.	Zhang H, Wu Y, Lin Z, et al. Naproxen for the treatment of neoplastic fever: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine (Baltimore), 2019, 98(22): e15840.
134.	Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study[J]. Crit Care, 2012, 16(1): R33.
135.	Lindholm E, Daneryd P, K?rner U, et al. Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients[J]. Clin Cancer Res, 2004, 10(20): 6855-6864.
136.	朱琦, 唐文富, 張穎. 補氣中藥治療癌性疲勞隨機對照臨床研究文獻Meta分析[J]. 海軍醫學雜志, 2015, (4): 302-307.
137.	許可依, 胡凱文, 孫健豪, 等. 中藥注射液治療癌因性疲乏的網狀Meta分析[J]. 世界科學技術-中醫藥現代化, 2023, 25(12): 4017-4031.
138.	Currow DC, Stevenson JP, Abernethy AP, et al. Prescribing in palliative care as death approaches[J]. J Am Geriatr Soc, 2007, 55(4): 590-595.
139.	Ferro-Uriguen A, Beobide-Telleria I, Gil-Goikouria J, et al. Application of a person-centered prescription model improves pharmacotherapeutic indicators and reduces costs associated with pharmacological treatment in hospitalized older patients at the end of life[J]. Front Public Health, 2022, 10: 994819.
140.	Tjia J, Clayton MF, Puerto G, et al. Shared medication planning in home hospice to address medication regimen complexity and family caregiver burden: a brief report[J]. J Palliat Med, 2024, 27(12): 1653-1656.

1. Cruz-Oliver DM. Palliative care: an update[J]. Miss Med, 2017, 114(2): 110-115.
2. Hu X, Yu SJ, Gao YC, et al. Health inequality in the disease burden of non-communicable diseases among the elderly from 1990 to 2021, and projections to 2050: a systematic analysis of global burden of disease study[J]. BMC Geriatr, 2025, 25(1): 693.
3. Ijaopo EO, Zaw KM, Ijaopo RO, et al. A review of clinical signs and symptoms of imminent end-of-life in individuals with advanced illness[J]. Gerontol Geriatr Med, 2023, 9: 23337214231183243.
4. Gon?alves F, Gaudêncio M, Rocha A, et al. A review on the management of symptoms in patients with incurable cancer[J]. Curr Oncol, 2025, 32(8): 433.
5. Swetz KM, Kamal AH. Palliative care[J]. Ann Intern Med, 2018, 168(5): 33-48.
6. Luo S, Chen W, Li J, et al. Association between multimorbidity and end-of-life outcomes among middle-aged and older adults: evidence from 28 countries[J]. J Am Med Direct Associat, 2025, 26(3): 105461.
7. Llop-Medina L, Fu Y, Garcés-Ferrer J, et al. Palliative care in older people with multimorbidities: a scoping review on the palliative care needs of patients, carers, and health professionals[J]. Int J Environ Res Public Health, 2022, 19(6): 3195.
8. 海峽兩岸醫藥衛生交流協會全科醫學分會. 姑息治療與安寧療護基本用藥指南[J]. 中國全科醫學, 2021, 24(14): 1717-1734.
9. Hagemann V, Bausewein C, Remi C. Off-label use in adult palliative care - more common than expected. A retrospective chart review[J]. Eur J Hosp Pharm, 2022, 29(6): 329-335.
10. Gr?dalski T. Polypharmacy and medication errors on admission to palliative care[J]. Pol Arch Intern Med, 2019, 129(10): 659-666.
11. Mozeluk NB, Gallo Acosta CM, Cunha Ferre MF, et al. Potentially inappropriate medication in older adults with palliative care at home[J]. Medicina (B Aires), 2024, 84(3): 487-495.
12. 李代萍, 王洋, 楊燕武, 等. 老年安寧療護患者癥狀管理用藥指南(2025)計劃書[J]. 中國循證醫學雜志, 2025, 25(12): 1384-1388.
13. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650): 924-926.
14. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64(4): 401-406.
15. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)[J]. J Clin Epidemiol, 2011, 64(4): 407-415.
16. Guyatt GH, Alonso-Coello P, Schünemann HJ, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group[J]. J Clin Epidemiol, 2016, 80: 3-7.
17. Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline[J]. J Clin Oncol, 2023, 41(4): 914-930.
18. Principles of pain control in palliative care for adults. Guidance prepared by a working group of the ethical issues in medicine committee of the royal college of physicians[J]. J R Coll Physicians Lond, 2000, 34(4): 350-352.
19. Hodgkinson S, Ruegger J, Field-Smith A, et al. Care of dying adults in the last days of life[J]. Clin Med (Lond), 2016, 16(3): 254-258.
20. Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy[J]. Support Care Cancer, 2005, 13(11): 888-894.
21. Nijland L, Schmidt P, Frosch M, et al. Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review[J]. Support Care Cancer, 2019, 27(1): 33-42.
22. Wegman A, van der Windt D, van Tulder M, et al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee. A systematic review of evidence and guidelines[J]. J Rheumatol, 2004, 31(2): 344-354.
23. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis. A meta-analysis of randomised controlled trials[J]. Ann Rheum Dis, 2004, 63(8): 901-907.
24. Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis[J]. Pain, 2009, 143(3): 238-245.
25. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis[J]. BMC Musculoskelet Disord, 2004, 5: 28.
26. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients[J]. Drug Saf, 2008, 31(6): 545-556.
27. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials[J]. Lancet, 2013, 382(9894): 769-779.
28. Bosnjak S, Jelic S, Susnjar S, et al. Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study[J]. J Chemother, 2002, 14(2): 214-219.
29. La Spina I, Porazzi D, Maggiolo F, et al. Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations[J]. Eur J Neurol, 2001, 8(1): 71-75.
30. Takahashi H, Shimoyama N. A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain[J]. Int J Clin Oncol, 2010, 15(1): 46-51.
31. Wen C, Wang M, Liu M, et al. Pregabalin combined with opioids for managing neuropathic pain in patients with cancer: a systematic review and meta-analysis of randomized controlled trials[J]. Pain Physician, 2025, 28(1): 1-10.
32. Hui D, Bohlke K, Bao T, et al. Management of dyspnea in advanced cancer: ASCO guideline[J]. J Clin Oncol, 2021, 39(12): 1389-1411.
33. Hui D, Maddocks M, Johnson MJ, et al. Management of breathlessness in patients with cancer: ESMO clinical practice guidelines[J]. ESMO Open, 2020, 5(6): e001038.
34. Kloke M, Cherny N. Treatment of dyspnoea in advanced cancer patients: ESMO clinical practice guidelines[J]. Ann Oncol, 2015, 26(Suppl 5): v169-v173.
35. Yamaguchi Y, Saif-Ur-Rahman KM, Nomura M, et al. Opioid prescription method for breathlessness due to non-cancer chronic respiratory diseases: a systematic review[J]. Int J Environ Res Public Health, 2022, 19(8): 4907.
36. Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial[J]. JAMA Intern Med, 2020, 180(10): 1306-1314.
37. Ekstrom M, Ferreira D, Chang S, et al. Effect of regular, low-dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: the BEAMS randomized clinical trial. Multicenter study randomized controlled trial research support, non-U. S. Gov't[J]. JAMA, 2022, 328(20): 2022-2032.
38. Currow D, Louw S, McCloud P, et al. Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial[J]. Thorax, 2020, 75(1): 50-56.
39. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea[J]. BMJ, 2003, 327(7414): 523-528.
40. Gomutbutra P, O'Riordan DL, Pantilat SZ. Management of moderate-to-severe dyspnea in hospitalized patients receiving palliative care[J]. J Pain Symptom Manage, 2013, 45(5): 885-891.
41. Clemens KE, Klaschik E. Dyspnoea associated with anxiety-symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients[J]. Support Care Cancer, 2011, 19(12): 2027-2033.
42. Kako J, Kobayashi M, Oosono Y, et al. Immediate effect of fan therapy in terminal cancer with dyspnea at rest: a meta-analysis[J]. Am J Hosp Palliat Care, 2020, 37(4): 294-299.
43. Gallagher R, Roberts D. A systematic review of oxygen and airflow effect on relief of dyspnea at rest in patients with advanced disease of any cause[J]. J Pain Palliat Care Pharmacotherapy, 2004, 18(4): 3-15.
44. Uronis HE, Currow DC, McCrory DC, et al. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis[J]. Br J Cancer, 2008, 98(2): 294-299.
45. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial[J]. Lancet, 2010, 376(9743): 784‐793.
46. Hui D, Hernandez F, Urbauer D, et al. High-flow oxygen and high-flow air for dyspnea in hospitalized patients with cancer: a pilot crossover randomized clinical trial[J]. Oncologist, 2021, 26(5): 883-892.
47. Hui D, Morgado M, Chisholm G, et al. High-flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: a phase Ⅱ randomized trial[J]. J Pain Sympt Manag, 2013, 46(4): 463-473.
48. Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough[J]. J Int Med Res, 1983, 11(2): 92-100.
49. Smith J, Owen E, Earis J, et al. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2006, 117(4): 831-835.
50. 陳夢婷, 肖小意, 余慧青, 等. 復方福爾可定糖漿與復方可待因口服溶液用于肺癌相關性咳嗽療效觀察[J]. 中華醫學雜志, 2023, 103(13): 975-980.
51. 喬敬敬. 不同劑量鹽酸氨溴索治療老年慢性支氣管炎的臨床效果對比[J]. 航空航天醫學雜志, 2018, 29(5): 593-595.
52. 于春紅. 鹽酸氨溴索與頭孢曲松鈉在老年慢性支氣管炎中的應用效果分析[J]. 中國實用醫藥, 2025, 20(13): 86-89.
53. 余權標, 謝鋒, 劉鐵柱, 等. 噻托溴銨聯合鹽酸氨溴索治療老年COPD急性期的療效觀察[J]. 北方藥學, 2016, 13(10): 14-15.
54. 凌方英. 抗生素聯合氨溴索治療老年慢性支氣管炎急性發作的臨床效果分析[J]. 心血管外科雜志(電子版), 2018, 7(3): 468-469.
55. 盧真其, 蔡勤聰, 王彩華, 等. 鹽酸氨溴索治療老年慢性支氣管炎急性發作的臨床分析[J]. 中國現代藥物應用, 2019, 13(9): 106-107.
56. 李抒菡. 鹽酸氨溴索治療老年慢性支氣管炎急性期的臨床效果觀察[J]. 中國醫藥指南, 2015, (16): 176-176.
57. 柴鶴萍. 老年慢性支氣管炎64例臨床分析[J]. 中國初級衛生保健, 2015, 29(3): 126.
58. 賀燕. 鹽酸氨溴索聯合頭孢曲松鈉治療老年慢性支氣管炎的效果[J]. 臨床合理用藥雜志, 2021, 14(7): 50-51.
59. 姬改娜, 薛世民, 周娟. 羧甲司坦片聯合CPAP治療老年OSAHS患者的效果[J]. 貴州醫藥, 2022, 46(6): 877-878.
60. 張君. 羧甲司坦口服液治療>65歲肺炎患者臨床觀察[J]. 中國實用醫藥, 2012, 7(23): 175-176.
61. Tsai YS, Hsu LW, Wu MS, et al. Effects of tranexamic acid on hemoptysis: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Drug Investig, 2020, 40(9): 789-797.
62. Mahalingam S, Rajendran G, Ramkumar A, et al. Effectiveness of inhalational tranexamic acid in patients with nonmassive hemoptysis-a systematic review and meta-analysis[J]. Lung, 2025, 203(1): 19.
63. Ye M, Chen M, Wang C, et al. Nebulized tranexamic acid in the management of hemoptysis: an integrative review[J]. Lung, 2025, 203(1): 28.
64. Wang Y, Wang X, Fu H, et al. Yunnan Baiyao adjuvant treatment for patients with hemoptysis: a systematic review and meta-analysis[J]. Evid Based Complement Alternat Med, 2022, 2022: 4931284.
65. 北京醫師協會呼吸內科專科醫師分會咯血診治專家共識編寫組. 咯血診治專家共識[J]. 中國呼吸與危重監護雜志, 2020, 19(1): 1-11.
66. Howard WJ, Rosario EJ, Calhoon SL. Hemoptysis. Causes and a practical management approach[J]. Postgrad Med, 1985, 77(8): 53-57.
67. Ruiz-García V, López-Briz E, Carbonell-Sanchis R, et al. Megestrol acetate for cachexia-anorexia syndrome. A systematic review[J]. J Cachexia Sarcopenia Muscle, 2018, 9(3): 444-452.
68. Miller S, McNutt L, McCann MA, et al. Use of corticosteroids for anorexia in palliative medicine: a systematic review[J]. J Palliat Med, 2014, 17(4): 482-485.
69. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial[J]. Support Care Cancer, 2010, 18(8): 951-956.
70. Mercadante S, Ripamonti C, Casuccio A, et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction[J]. Support Care Cancer, 2000, 8(3): 188-191.
71. Peng X, Wang P, Li S, et al. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer[J]. World J Surg Oncol, 2015, 13: 50.
72. Hisanaga T, Shinjo T, Morita T, et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction[J]. Jpn J Clin Oncol, 2010, 40(8): 739-745.
73. Piechotta V, Adams A, Haque M, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, (11): CD012775.
74. Franzén L, Nyman J, Hagberg H, et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy[J]. Ann Oncol, 1996, 7(6): 587-592.
75. Lanciano R, Sherman DM, Michalski J, et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy[J]. Cancer Invest, 2001, 19(8): 763-772.
76. Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial[J]. JAMA Oncol, 2020, 6(6): 895-899.
77. Khuroo MS, Khuroo MS, Farahat KL, et al. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis[J]. J Gastroenterol Hepatol, 2005, 20(1): 11-25.
78. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding[J]. Health Technol Assess, 2007, 11(51): iii-iv, 1-164.
79. Wang CH, Ma MH, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials[J]. Arch Intern Med, 2010, 170(9): 751-758.
80. Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices[J]. Hepatology, 1989, 10(6): 958-961.
81. Harris DG, Noble SI. Management of terminal hemorrhage in patients with advanced cancer: a systematic literature review[J]. J Pain Symptom Manage, 2009, 38(6): 913-927.
82. Sharif S, Kang J, Sadeghirad B, et al. Pharmacological agents for procedural sedation and analgesia in the emergency department and intensive care unit: a systematic review and network meta-analysis of randomised trials[J]. Br J Anaesth, 2024, 132(3): 491-506.
83. Assmann SL, Keszthelyi D, Kleijnen J, et al. Guideline for the diagnosis and treatment of Faecal Incontinence-A UEG/ESCP/ESNM/ESPCG collaboration[J]. United European Gastroenterol J, 2022, 10(3): 251-286.
84. Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults[J]. Cochrane Database Syst Rev, 2013, (6): CD002116.
85. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea[J]. Gastroenterology, 1980, 79(6): 1272-1275.
86. Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial[J]. J Clin Oncol, 1993, 11(1): 148-151.
87. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy[J]. Anticancer Drugs, 1993, 4(4): 443-445.
88. Geller RB, Gilmore CE, Dix SP, et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients[J]. Am J Hematol, 1995, 50(3): 167-172.
89. Dzier?anowski T, Zaj?c A, Cia?kowska-Rysz A, et al. Constipation in palliative care patients - clinical practice guidelines[J]. Palliat Med, 2025, 17: 1-13.
90. Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review[J]. Am J Gastroenterol, 2021, 116(6): 1156-1181.
91. Jesuyajolu DA, Abubakar AK, Kowe T, et al. The management of opioid-induced constipation in cancer and advanced illness: a meta-analysis[J]. J Pain Symptom Manage, 2024, 67(4): e285-e297.
92. Hurdon V, Viola R, Schroder C. How useful is docusate in patients at risk for constipation. A systematic review of the evidence in the chronically ill[J]. J Pain Symptom Manage, 2000, 19(2): 130-136.
93. Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase Ⅲ studies[J]. Int J Clin Pract, 2013, 67(7): 619-632.
94. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase Ⅱ study (SYMPHONY)[J]. World J Urol, 2017, 35(5): 827-838.
95. Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE)[J]. Eur Urol, 2016, 70(1): 136-145.
96. Herdman M, Nazir J, Hakimi Z, et al. Assessing preference-based outcome measures for overactive bladder: an evaluation of patient-reported outcome data from the BESIDE clinical trial[J]. Patient, 2017, 10(6): 677-686.
97. Jiang F, Zhu L, Xu T, et al. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women-a multicenter, randomized, open-label, controlled comparison study[J]. Menopause, 2016, 23(4): 451-457.
98. Ashrafi F, Mousavi S, Karimi M. Potential role of bupropion sustained release for cancer-related fatigue: a double-blind, placebo-controlled study[J]. Asian Pac J Cancer Prev, 2018, 19(6): 1547-1551.
99. Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial-a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine[J]. Health Technol Assess, 2013, 17(7): 1-166.
100. Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer[J]. Acta Psychiatr Scand Suppl, 1985, 320: 85-92.
101. Eiser N, Harte R, Spiros K, et al. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD[J]. Copd, 2005, 2(2): 233-241.
102. Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group[J]. J Clin Oncol, 2003, 21(10): 1937-1943.
103. Friedli K, Guirguis A, Almond M, et al. Sertraline versus placebo in patients with major depressive disorder undergoing hemodialysis: a randomized, controlled feasibility trial[J]. Clin J Am Soc Nephrol, 2017, 12(2): 280-286.
104. Higginson IJ, Brown ST, Oluyase AO, et al. Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial[J]. Lancet Respir Med, 2024, 12(10): 763-774.
105. Hunter CN, Abdel-Aal HH, Elsherief WA, et al. Mirtazapine in cancer-associated anorexia and cachexia: a double-blind placebo-controlled randomized trial[J]. J Pain Symptom Manage, 2021, 62(6): 1207-1215.
106. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen[J]. Breast J, 2006, 12(2): 114-122.
107. Lacasse Y, Beaudoin L, Rousseau L, et al. Randomized trial of paroxetine in end-stage COPD[J]. Monaldi Arch Chest Dis, 2004, 61(3): 140-147.
108. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS[J]. Arch Gen Psychiatry, 2003, 60(7): 737-746.
109. Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study[J]. Am J Psychiatry, 2000, 157(10): 1686-1689.
110. Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease[J]. Am J Geriatr Psychiatry, 2000, 8(1): 66-74.
111. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program[J]. J Clin Oncol, 2003, 21(24): 4635-4641.
112. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial[J]. J Am Coll Cardiol, 2010, 56(9): 692-699.
113. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease[J]. Int Psychogeriatr, 2001, 13(2): 233-240.
114. Rascol O, Cochen de Cock V, Pavy-Le Traon A, et al. Fluoxetine for the symptomatic treatment of multiple system atrophy: the MSA-FLUO trial[J]. Mov Disord, 2021, 36(7): 1704-1711.
115. Razavi D, Allilaire JF, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients[J]. Acta Psychiatr Scand, 1996, 94(3): 205-210.
116. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy[J]. Breast Cancer Res Treat, 2005, 89(3): 243-249.
117. Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease[J]. Am J Geriatr Psychiatry, 2010, 18(2): 136-145.
118. Salehifar E, Azimi S, Janbabai G, et al. Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial[J]. BMC Cancer, 2020, 20(1): 158.
119. van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin[J]. Br J Psychiatry, 1996, 169(4): 440-443.
120. Ainsworth NJ, Marawi T, Maslej MM, et al. Cognitive outcomes after antidepressant pharmacotherapy for late-life depression: a systematic review and meta-analysis[J]. Am J Psychiatry, 2024, 181(3): 234-245.
121. Candy B, Jackson KC, Jones L, et al. Drug therapy for symptoms associated with anxiety in adult palliative care patients[J]. Cochrane Database Syst Rev, 2012, (10): CD004596.
122. Kotlinska-Lemieszek A, Klepstad P, Haugen DF. Clinically significant drug-drug interactions involving medications used for symptom control in patients with advanced malignant disease: a systematic review[J]. J Pain Symptom Manage, 2019, 57(5): 989-998.
123. Centeno C, Sanz A, Cuervo MA, et al. Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients[J]. BMJ Support Palliat Care, 2012, 2(4): 328-333.
124. Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial[J]. J Pain Symptom Manage, 2012, 43(1): 68-77.
125. Stone PC, Minton O, Richardson A, et al. Methylphenidate versus placebo for treating fatigue in patients with advanced cancer: randomized, double-blind, multicenter, placebo-controlled trial[J]. J Clin Oncol, 2024, 42(20): 2382-2392.
126. 王雪芹, 于欣, 高旭光, 等. 唑吡坦治療老年原發性失眠的開放性前瞻性多中心自身對照研究[J]. 中華精神科雜志, 2010, 43(2): 106-110.
127. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety[J]. BMC Med, 2010, 8: 51.
128. Marupuru S, Arku D, Campbell AM, et al. Use of melatonin and/on ramelteon for the treatment of insomnia in older adults: a systematic review and meta-analysis[J]. J Clin Med, 2022, 11(17): 1-17.
129. Agar MR, Lawlor PG, Quinn S, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial[J]. JAMA Intern Med, 2017, 177(1): 34-42.
130. Bush SH, Bruera E, Lawlor PG, et al. Clinical practice guidelines for delirium management: potential application in palliative care[J]. J Pain Symptom Manage, 2014, 48(2): 249-258.
131. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial[J]. JAMA, 2017, 318(11): 1047-1056.
132. Ferraz Gon?alves JA, Almeida A, Costa I, et al. Comparison of haloperidol alone and in combination with midazolam for the treatment of acute agitation in an inpatient palliative care service[J]. J Pain Palliat Care Pharmacother, 2016, 30(4): 284-288.
133. Zhang H, Wu Y, Lin Z, et al. Naproxen for the treatment of neoplastic fever: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine (Baltimore), 2019, 98(22): e15840.
134. Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study[J]. Crit Care, 2012, 16(1): R33.
135. Lindholm E, Daneryd P, K?rner U, et al. Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients[J]. Clin Cancer Res, 2004, 10(20): 6855-6864.
136. 朱琦, 唐文富, 張穎. 補氣中藥治療癌性疲勞隨機對照臨床研究文獻Meta分析[J]. 海軍醫學雜志, 2015, (4): 302-307.
137. 許可依, 胡凱文, 孫健豪, 等. 中藥注射液治療癌因性疲乏的網狀Meta分析[J]. 世界科學技術-中醫藥現代化, 2023, 25(12): 4017-4031.
138. Currow DC, Stevenson JP, Abernethy AP, et al. Prescribing in palliative care as death approaches[J]. J Am Geriatr Soc, 2007, 55(4): 590-595.
139. Ferro-Uriguen A, Beobide-Telleria I, Gil-Goikouria J, et al. Application of a person-centered prescription model improves pharmacotherapeutic indicators and reduces costs associated with pharmacological treatment in hospitalized older patients at the end of life[J]. Front Public Health, 2022, 10: 994819.
140. Tjia J, Clayton MF, Puerto G, et al. Shared medication planning in home hospice to address medication regimen complexity and family caregiver burden: a brief report[J]. J Palliat Med, 2024, 27(12): 1653-1656.

Next Article
The clinical practice guidelines for discharge planning of patients with stroke

Chinese Journal of Evidence-Based Medicine

Guideline for medication management of symptoms in older palliative care patients (2025)

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content